Fludeoxyglucose F 18 PET/CT Assessment of Ovarian Cancer

PET Clin. 2018 Apr;13(2):179-202. doi: 10.1016/j.cpet.2017.11.005. Epub 2018 Jan 10.

Abstract

Ovarian cancer is one of the most common gynecologic cancers and one of the leading causes of cancer death in women. It is often asymptomatic in early stages, and thus most patients are diagnosed when it is of advanced stage. For these reasons, the role of biomarkers and tomographic imaging is crucial. Fludeoxyglucose F 18 PET/CT is a useful imaging modality in different clinical settings of the disease, overcoming some limits of conventional imaging and influencing prognosis and therapeutic approaches. PET/MR imaging is an emerging modality, and its potential role remains to be explored.

Keywords: Biomarkers; FDG PET/CT; Ovarian cancer; Prognosis; Response to treatment; Staging.

Publication types

  • Review

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Middle Aged
  • Neoplasm Invasiveness / pathology
  • Neoplasm Staging
  • Ovarian Neoplasms / diagnostic imaging*
  • Ovarian Neoplasms / pathology*
  • Positron Emission Tomography Computed Tomography / methods*
  • Practice Guidelines as Topic*
  • Radiographic Image Enhancement*
  • Sensitivity and Specificity

Substances

  • Fluorodeoxyglucose F18